Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
J He, R Zhang, M Shao, X Zhao, M Miao, J Chen… - Annals of the rheumatic …, 2020 - Elsevier
Objectives Open-labelled clinical trials suggested that low-dose IL-2 might be effective in
treatment of systemic lupus erythematosus (SLE). A double-blind and placebo-controlled
trial is required to formally evaluate the safety and efficacy of low-dose IL-2 therapy. Methods
A randomised, double-blind and placebo-controlled clinical trial was designed to treat 60
patients with active SLE. These patients received either IL-2 (n= 30) or placebo (n= 30) with
standard treatment for 12 weeks, and were followed up for additional 12 weeks. IL-2 at a …
treatment of systemic lupus erythematosus (SLE). A double-blind and placebo-controlled
trial is required to formally evaluate the safety and efficacy of low-dose IL-2 therapy. Methods
A randomised, double-blind and placebo-controlled clinical trial was designed to treat 60
patients with active SLE. These patients received either IL-2 (n= 30) or placebo (n= 30) with
standard treatment for 12 weeks, and were followed up for additional 12 weeks. IL-2 at a …
